Home » Stocks » VCEL

Vericel Corporation (VCEL)

Stock Price: $53.46 USD -1.31 (-2.39%)
Updated Apr 20, 2021 4:00 PM EDT - Market closed
After-hours: $52.65 -0.81 (-1.52%) Apr 20, 5:35 PM
Market Cap 2.50B
Revenue (ttm) 124.18M
Net Income (ttm) 2.86M
Shares Out 45.22M
EPS (ttm) 0.06
PE Ratio 891.00
Forward PE 312.50
Dividend n/a
Dividend Yield n/a
Trading Day April 20
Last Price $53.46
Previous Close $54.77
Change ($) -1.31
Change (%) -2.39%
Day's Open 54.75
Day's Range 51.26 - 55.21
Day's Volume 637,188
52-Week Range 12.23 - 60.49

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

CAMBRIDGE, Mass., April 09, 2021 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Nick Col...

1 week ago - GlobeNewsWire

The company will be a component of a well-known small-cap stock index.

1 month ago - The Motley Fool

NEW YORK, March 17, 2021 /PRNewswire/ -- Vericel Corp. (NASD:VCEL) will replace QEP Resources Inc. (NYSE:QEP) in the S&P SmallCap 600 effective prior to the opening of trading on Monday, March 22. S&P 5...

Other stocks mentioned: QEP
1 month ago - PRNewsWire

In the latest trading session, Vericel Corporation (VCEL) closed at $42.92, marking a -0.26% move from the previous day.

1 month ago - Zacks Investment Research

CAMBRIDGE, Mass., March 10, 2021 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Nick Col...

1 month ago - GlobeNewsWire

Sometimes valuation metrics can be deceiving.

Other stocks mentioned: HALO
1 month ago - The Motley Fool

Vericel Corporation (VCEL) delivered earnings and revenue surprises of 19.05% and 0.40%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

1 month ago - Zacks Investment Research

Shares of Vericel (NASDAQ:VCEL) rose 1.0% in pre-market trading after the company reported Q4 results. Quarterly Results Earnings per share were up 25.00% year over year to $0.25, which beat the estimat...

1 month ago - Benzinga

CAMBRIDGE, Mass., Feb. 22, 2021 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Nick Cola...

1 month ago - GlobeNewsWire

In the latest trading session, Vericel Corporation (VCEL) closed at $51.15, marking a -0.04% move from the previous day.

2 months ago - Zacks Investment Research

Vericel Corporation (VCEL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

2 months ago - Zacks Investment Research

Is (VCEL) Outperforming Other Medical Stocks This Year?

2 months ago - Zacks Investment Research

CAMBRIDGE, Mass., Feb. 16, 2021 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Nick Cola...

2 months ago - GlobeNewsWire

CAMBRIDGE, Mass., Feb. 12, 2021 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that its Board...

2 months ago - GlobeNewsWire

Vericel Corporation (VCEL) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

2 months ago - Zacks Investment Research

Bull of the Day: Vericel (VCEL)

2 months ago - Zacks Investment Research

CAMBRIDGE, Mass., Jan. 25, 2021 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, announced the appointment of J...

2 months ago - GlobeNewsWire

CAMBRIDGE, Mass., Jan. 08, 2021 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Nick Cola...

3 months ago - GlobeNewsWire

CAMBRIDGE, Mass., Jan. 07, 2021 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that UnitedHea...

3 months ago - GlobeNewsWire

Vericel is a high growth, disruptive biotechnology company with annual sales increasing at a 30% rate prior to the COVID-19 pandemic. The Company's tissue repair and restoration products are proprietary...

3 months ago - Seeking Alpha

The company's earnings are expected to increase exponentially in 2021

3 months ago - GuruFocus

CAMBRIDGE, Mass., Dec. 18, 2020 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Nick Cola...

4 months ago - GlobeNewsWire

Vericel is a low-risk, high-quality small biotech with high growth potential. The business is already profitable with 70% gross profit margin and no debt on the balance sheet.

4 months ago - Seeking Alpha

Vericel Corporation (VCEL) CEO Nick Colangelo on Q3 2020 Results - Earnings Call Transcript

5 months ago - Seeking Alpha

Total Net Revenues of $32.3 Million and Net Income of $3.6 Million

5 months ago - GlobeNewsWire

Technology won't always be on top. There's a bunch of budding industries that could prove to be winners over the next 5 years.

Other stocks mentioned: EXAS, INMD, QQQ, XLK
5 months ago - Zacks Investment Research

Bull of the Day: Vericel (VCEL)

5 months ago - Zacks Investment Research

CAMBRIDGE, Mass., Nov. 02, 2020 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced presentations ...

5 months ago - GlobeNewsWire

Vericel Corp (VCEL) has been struggling lately, but the selling pressure may be coming to an end soon.

5 months ago - Zacks Investment Research

CAMBRIDGE, Mass., Oct. 22, 2020 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced the following ...

5 months ago - GlobeNewsWire

Double-Digit Revenue, Implant and Biopsy Growth for MACI in the Quarter and Record Monthly Biopsies in September

6 months ago - GlobeNewsWire

CAMBRIDGE, Mass., Oct. 09, 2020 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, will host a virtual Analyst an...

6 months ago - GlobeNewsWire

CAMBRIDGE, Mass., Sept. 16, 2020 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ: VCEL) today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing the recently submitted ...

7 months ago - GlobeNewsWire

CAMBRIDGE, Mass., Sept. 09, 2020 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced presentatio...

7 months ago - GlobeNewsWire

CAMBRIDGE, Mass., Sept. 04, 2020 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Nick C...

7 months ago - GlobeNewsWire

YAVNE, Israel and CAMBRIDGE, Mass., Aug. 25, 2020 (GLOBE NEWSWIRE) -- MediWound Ltd. (NASDAQ: MDWD) and its U.S. commercial partner Vericel Corporation (NASDAQ: VCEL) today announced that the Biomedic...

Other stocks mentioned: MDWD
7 months ago - GlobeNewsWire

Vericel Corporation (VCEL) CEO Nick Colangelo on Q2 2020 Results - Earnings Call Transcript

8 months ago - Seeking Alpha

Product Revenues of $20.0 Million Reported for the Second Quarter

8 months ago - GlobeNewsWire

CAMBRIDGE, Mass., July 22, 2020 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced the followin...

8 months ago - GlobeNewsWire

Investors need to pay close attention to Vericel (VCEL) stock based on the movements in the options market lately.

9 months ago - Zacks Investment Research

Second Quarter Net Product Revenues Expected to be Approximately $20 Million Second Quarter Net Product Revenues Expected to be Approximately $20 Million

9 months ago - GlobeNewsWire

CAMBRIDGE, Mass., June 30, 2020 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ: VCEL) today announced the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration ...

9 months ago - GlobeNewsWire

Identifying toxic stocks and discarding them at the right time is the key to guard your portfolio from big losses.

Other stocks mentioned: CNK, IDXX, MYGN
10 months ago - Zacks Investment Research

Vericel's (VCEL) CEO Nick Colangelo on Q1 2020 Results - Earnings Call Transcript

11 months ago - Seeking Alpha

Shares of Vericel (NASDAQ:VCEL) rose 2.2% after the company reported Q1 results. Quarterly Results Earnings per share fell 42.86% year over year to ($0.10), which missed the estimate of ($0.08).

11 months ago - Benzinga

Vericel Corporation: A Must-Have Biotech Post-COVID-19 Sell-Off - Behind The Idea

1 year ago - Seeking Alpha

Vericel Is Substantially Undervalued Given Strong Balance Sheet, Profitability And Competitive Advantages

1 year ago - Seeking Alpha

Accurately identifying toxic stocks and abandoning or short selling those at the right time is the key to safeguard your portfolio from big losses.

Other stocks mentioned: AG, CWST, ENV, MYGN
1 year ago - Zacks Investment Research

Vericel Corp (VCEL) CEO Dominick Colangelo on Q4 2019 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

About VCEL

Vericel Corporation, a commercial-stage biopharmaceutical company, researches, develops, manufactures, and distributes cellular therapies for sports medicine and severe burn care markets in the United States. The company markets autologous cell therapy products comprising MACI, an autologous cellularized scaffold product for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; and Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-de... [Read more...]

Industry
Biotechnology
IPO Date
Feb 4, 1997
CEO
Dominick Colangelo
Employees
273
Stock Exchange
NASDAQ
Ticker Symbol
VCEL
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 8 analysts, the average rating for Vericel stock is "Strong Buy." The 12-month stock price forecast is 61.21, which is an increase of 14.50% from the latest price.

Price Target
$61.21
(14.50% upside)
Analyst Consensus: Strong Buy